Itaconate Starves Lung Tumors by Blocking a Key Metabolic Enzyme
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
Summary
Researchers discovered that itaconate, a metabolite produced by immune cells called macrophages, naturally suppresses lung tumor growth — but tumors actively deplete it. Using spatial metabolomics and single-cell RNA sequencing in human and mouse lung cancers, the team showed that the enzyme IRG1, which makes itaconate, is primarily expressed in macrophages within tumors. When IRG1 was removed, tumors grew faster. Treating tumors with a modified form of itaconate called 4-octyl itaconate (Octyl Ita) slowed cancer growth in lab cultures, animal models, and fresh human tumor tissue. The mechanism: itaconate blocks glucose-6-phosphate dehydrogenase (G6PD), shutting down the pentose phosphate pathway that tumors rely on for growth, while simultaneously converting pro-tumor macrophages into anti-tumor ones. This dual action makes itaconate a compelling candidate for lung cancer therapy.
Detailed Summary
Lung cancer remains one of the deadliest malignancies worldwide, and the tumor microenvironment — particularly tumor-associated macrophages (TAMs) — plays a decisive role in whether a tumor grows or is controlled. Most TAMs are co-opted by tumors to support growth, but this study reveals a natural immune brake that tumors actively suppress: the itaconate pathway.
Researchers from Justus Liebig University and the Max Planck Institute investigated the role of IRG1, the enzyme responsible for producing itaconate within macrophages, in lung cancer. Using spatial metabolomics, they found that endogenous itaconate is markedly depleted specifically within tumor regions compared to adjacent healthy lung tissue — suggesting tumors actively suppress this anti-cancer metabolite.
Single-cell RNA sequencing confirmed macrophages as the dominant IRG1-expressing cells in both human and mouse lung tumors. Critically, when IRG1 was genetically knocked out — or when bone marrow lacking IRG1 was transplanted into mice — lung tumors grew significantly faster, establishing a causal tumor-suppressive role for the IRG1/itaconate axis.
A multi-omics analysis revealed the mechanism: itaconate inhibits glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway (PPP). Cancer cells and pro-tumor macrophages both depend on PPP activity for biosynthesis and redox balance. By blocking G6PD, itaconate simultaneously starves cancer cells of growth substrates and reprograms pro-tumor macrophages into an anti-tumor phenotype. Treatment with 4-octyl itaconate (Octyl Ita), a cell-permeable derivative, reduced tumor growth in cell cultures, mouse models, and ex vivo human precision-cut lung slices.
Caveats include that the full paper was not accessible — this summary is based on the abstract alone. Translational questions remain, including optimal delivery, dosing, and potential off-target metabolic effects of Octyl Ita in human patients.
Key Findings
- Itaconate is depleted inside lung tumors, suggesting tumors actively suppress this natural anti-cancer metabolite.
- Removing IRG1 in mice accelerates lung tumor growth, confirming a causal tumor-suppressive role.
- Itaconate blocks G6PD, disrupting the pentose phosphate pathway that cancer cells rely on for growth.
- 4-octyl itaconate slows tumor growth in cell cultures, mouse models, and fresh human tumor tissue.
- Itaconate reprograms pro-tumor macrophages into anti-tumor macrophages, providing a dual attack on cancer.
Methodology
The study used spatial metabolomics, single-cell RNA sequencing, IRG1 knockout mouse models, bone marrow transplantation experiments, and multi-omics analysis across human lung tumors, mouse models, and ex vivo precision-cut lung slices. The combination of genetic loss-of-function and pharmacological rescue with 4-octyl itaconate strengthens causal inference.
Study Limitations
Detailed statistical analyses, dose-response data, and supplementary findings beyond the abstract are not reviewed here. Translation to human clinical settings requires further pharmacokinetic and toxicology data for Octyl Ita. The long-term durability of macrophage reprogramming by itaconate in human tumors has not yet been established. Findings rely heavily on mouse models, and the ex vivo human precision-cut lung slice data, while supportive, is short-term.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.